Lonafarnib
Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It is known to target GTPase NRas, GTPase HRas, GTPase KRas, and protein farnesyltransferase subunit beta. Zokinvy's patent is valid until 2024-07-26 (FDA).
| Trade Name | Zokinvy |
|---|---|
| Common Name | Lonafarnib |
| Indication | |
| Drug Class | Farnesyl transferase inhibitor |
